Q3 EPS Estimates for Exact Sciences Cut by Leerink Partnrs

Key Points

• Leerink Partners has revised down its Q3 2025 earnings per share estimate for Exact Sciences to $0.16, from a prior estimate of $0.17.
• Exact Sciences recently reported earnings of $0.22 per share for the previous quarter, significantly beating analysts' consensus estimate of ($0.02) by $0.24.
• The stock has seen significant institutional interest, with 88.82% of shares currently owned by institutional investors, including Vanguard Group and Capital World Investors increasing their stakes.

Exact Sciences Corporation (NASDAQ:EXAS - Free Report) - Stock analysts at Leerink Partnrs dropped their Q3 2025 earnings per share estimates for Exact Sciences in a research note issued on Thursday, August 7th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings per share of $0.16 for the quarter, down from their previous estimate of $0.17. The consensus estimate for Exact Sciences' current full-year earnings is ($0.58) per share. Leerink Partnrs also issued estimates for Exact Sciences' Q4 2025 earnings at $0.21 EPS, Q1 2026 earnings at $0.17 EPS, Q2 2026 earnings at $0.29 EPS and Q3 2026 earnings at $0.34 EPS.

Several other equities analysts have also issued reports on the company. UBS Group lowered their price target on Exact Sciences from $61.00 to $53.00 and set a "neutral" rating on the stock in a research note on Thursday. Barclays lowered their price target on Exact Sciences from $65.00 to $55.00 and set an "overweight" rating on the stock in a research note on Thursday. Robert W. Baird boosted their price target on Exact Sciences from $69.00 to $72.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Evercore ISI cut their price target on shares of Exact Sciences from $68.00 to $64.00 and set an "outperform" rating for the company in a research note on Friday. Finally, Cowen restated a "buy" rating on shares of Exact Sciences in a research note on Thursday. Three research analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $68.62.

Exact Sciences Stock Performance

EXAS traded down $2.17 on Friday, hitting $40.99. 6,210,297 shares of the stock traded hands, compared to its average volume of 3,127,436. Exact Sciences has a 52 week low of $38.81 and a 52 week high of $72.83. The company has a current ratio of 2.89, a quick ratio of 2.38 and a debt-to-equity ratio of 0.94. The firm has a market capitalization of $7.76 billion, a PE ratio of -7.55, a P/E/G ratio of 8.75 and a beta of 0.93. The business has a fifty day moving average price of $51.55 and a two-hundred day moving average price of $50.03.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The medical research company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.24. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%. The firm had revenue of $811.09 million for the quarter, compared to analyst estimates of $774.43 million. During the same period in the previous year, the company posted ($0.09) earnings per share. The company's quarterly revenue was up 16.0% compared to the same quarter last year.

Insider Activity

In related news, Director Katherine S. Zanotti sold 3,207 shares of the business's stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $53.20, for a total value of $170,612.40. Following the completion of the transaction, the director owned 72,759 shares in the company, valued at $3,870,778.80. The trade was a 4.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 1.20% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of EXAS. Bank Pictet & Cie Europe AG raised its position in Exact Sciences by 1.2% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 129,024 shares of the medical research company's stock worth $7,250,000 after purchasing an additional 1,547 shares during the last quarter. Resona Asset Management Co. Ltd. bought a new position in Exact Sciences in the 4th quarter worth approximately $3,031,000. Aviva PLC bought a new position in Exact Sciences in the 4th quarter worth approximately $5,824,000. Cerity Partners LLC raised its position in Exact Sciences by 65.9% in the 4th quarter. Cerity Partners LLC now owns 27,090 shares of the medical research company's stock worth $1,541,000 after purchasing an additional 10,761 shares during the last quarter. Finally, Invesco Ltd. raised its position in Exact Sciences by 57.2% in the 4th quarter. Invesco Ltd. now owns 379,683 shares of the medical research company's stock worth $21,334,000 after purchasing an additional 138,089 shares during the last quarter. Institutional investors own 88.82% of the company's stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.